Clinical trials: Systemic Embolism
Vascular Access Complication
Vascular Access in Hematological Patients - PICC Versus CVC
The use of peripherally inserted central catheters (PICCs) represents a major advance for hematological patients, enabling the effective delivery of chemotherapy and/or blood products particularly for prolonged infusions or in…
- Trial name
- NCT02405728
- Testing
- Centrally inserted central catheters (CICCs), Peripherally inserted central catheters (PICCs)
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- Federico II University
Liver Cirrhosis, Portal Hypertension
Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement
Portal vein thrombosis is defined as non-tumoural obstruction of the portal vein or one of its branches. Its incidence is 0.7 to 2.7 per 100,000 patient-years in the general population, and 4.6 per 100 patient-years in patients…
- Trial name
- PORTHEMOST (NCT07439939)
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Secondary Raynaud's Phenomenon
Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon
The purpose of this study is to determine whether pl-vegf165 (Neovasculgen) is effective in the treatment of digital ulcers related to secondary Raynaud's phenomenon associated with systemic scleroderma
- Trial name
- NCT02356809
- Testing
- Neovasculgen
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Artgen Biotech
Systemic Sclerosis, Raynaud's Phenomenon
The Effects of Exercise in Patients With Systemic Sclerosis
Systemic sclerosis (SSc) is a multisystem connective tissue disease characterised by vascular abnormalities and fibrosis, including those of the skin and can be categorised as either Limited cutaneous scleroderma or Diffuse…
- Conditions
- Systemic Sclerosis, Raynaud's Phenomenon, Quality of Life
- Trial name
- NCT03058887
- Testing
- Exercise intervention - Cycling, Exercise intervention - arm cranking
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Sheffield Hallam University
Raynaud, Scleroderma
A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
Raynaud's phenomenon is thought to occur when, in response to cold or emotional stress, there is closure of the digital arteries and cutaneous arterioles leading to the clinical finding of sharp demarcated digital pallor and…
- Trial name
- NCT00498615
- Testing
- Fasudil
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Johns Hopkins University
Atrial Fibrillation
Clinical and Laboratory Predictors Associated With Stroke or Systemic Embolism in Low Risk Atrial Fibrillation Patients
The purposes of this study are to assess the prevalence of patients with a low risk of stroke or systemic embolism based on a CHA2DS2-VASc score among patients who have an AF-related thromboembolism and to identify the clinical…
- Trial name
- CLASS-AF (NCT03147911)
- Where
- 9 sites in South Korea
- Volunteers
- 1,181 people
- Sponsor
- Korea University Guro Hospital
Raynaud's Disease, Scleroderma
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
- Conditions
- Raynaud's Disease, Scleroderma, Autoimmune Diseases
- Trial name
- NCT00419419
- Testing
- Topical AmphiMatrix with nitroglycerin (MQX-503)
- Where
- 12 sites in United States, Sweden and 1 more
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- MediQuest Therapeutics
Cardiovascular Diseases, Coronary Disease
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
To study longitudinally the incidence, pathogenesis, and risk factors for thrombotic events and coronary artery disease in a cohort of patients with systemic lupus erythematosus (SLE).
- Conditions
- Cardiovascular Diseases, Coronary Disease, Thrombosis, Heart Diseases
- Trial name
- NCT00005436
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Venous Thromboembolism
Remote Home Prothrombin Time (PT)/International Normalized Ratio (INR) Monitoring and Patient Management System
Long-term anticoagulation is indicated in patients for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or mechanical cardiac valve replacement, prevention or treatment…
- Trial name
- vMetrics-AMS (NCT00978445)
- Testing
- vMetrics protocol
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- ZIN Technologies, Inc.
Systemic Sclerosis, Raynaud Phenomenon
Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis
In this feasibility study, we aim to explore therapeutic Rheopheresis (RheoP) as a novel treatment option for SSc-associated Raynaud's phenomenon and/or digital ulcers and compare it to the standard of care treatment (intravenous…
- Conditions
- Systemic Sclerosis, Raynaud Phenomenon, Digital Ulcer, Scleroderma
- Trial name
- RHEACT (NCT05204784)
- Testing
- Rheopheresis treatment, Intravenous Infusion
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Peter Korsten
Stroke, Prevention and Control
An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers
This is a retrospective observational study to describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism, who at least…
- Conditions
- Stroke, Prevention and Control, Atrial Fibrillation
- Trial name
- BRONCE-AP (NCT02559232)
- Testing
- Direct Oral Anticoagulant (DOAC)
- Where
- Spain
- Volunteers
- 247 people
- Sponsor
- Bayer
Age-related Macular Degeneration, Diabetic Macular Edema
Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
Comparable data for bevacizumab and aflibercept are lacking, as are studies comparing the systemic levels of ranibizumab, bevacizumab, and aflibercept and their relative effects on circulating vascular endothelial growth factor.
- Conditions
- Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT02118831
- Testing
- Blood Sample Collection, Aflibercept, Bevacizumab
- Volunteers
- 56 people
- Sponsor
- California Retina Consultants
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Raynaud's Phenomenon
Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon
Raynaud's phenomenon (RP) is a disorder of the digital blood vessels resulting in episodic impairment of blood flow. During an attack of RP which commonly affects the hands and feet these arteries contract briefly which limits…
- Trial name
- REINO (NCT01315899)
- Testing
- ORM-12471 30mg, ORM-12471
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Orion Corporation, Orion Pharma
Sars-CoV2, COVID
Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients
The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients with treatment dose LMWH leads to better thromboembolic-free outcomes and associated complications during hospitalization than…
- Trial name
- NCT04401293
- Testing
- Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
- Where
- 6 sites in United States
- Volunteers
- 257 people
- Sponsor
- Northwell Health
Scleroderma, Raynaud's Syndrome
Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
This is a randomized, double-blinded, clinical trial assessing the therapeutic efficacy of Botulinum toxin A (Onabotulinumtoxin A) in treating scleroderma-associated Raynaud's syndrome.
- Trial name
- NCT02165111
- Testing
- Onabotulinumtoxin A, sterile saline solution
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
Patients Who Underwent Percutaneous Lung Biopsy Under CT Guidance, Patients Who Presented Systemic Air Embolism After Percutaneous Lung Biopsy Under CT Guidance Depicted at the Time of the Procedure on a Whole Thoracic CT
Systemic Air Embolism After CT-guided Lung Biopsy
Systemic air embolism is traditionally considered as an extremely rare complication of percutaneous lung biopsy. Current literature includes mainly case reports or small case series of SAE.
- Trial name
- SAE (NCT03360084)
- Testing
- Percutaneous lung biopsy under CT guidance
- Where
- France
- Volunteers
- 559 people
- Sponsor
- University Hospital, Montpellier
Raynaud's Disease
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Juvenile secondary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears.
- Trial name
- NCT00048776
- Testing
- Pletal
- Where
- 19 sites in United States
- Volunteers
- 75 people
- Sponsor
- Otsuka America Pharmaceutical
Venous Thromboembolism, Anticoagulant-induced Bleeding
Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events
Venous thromboembolism affects around 10 million people per year worldwide, however, despite its high incidence, there is no systematic review or randomized trial focused on the treatment of patients with recurrent deep vein…
- Conditions
- Venous Thromboembolism, Anticoagulant-induced Bleeding, Venous Thromboses, Pulmonary Embolism
- Trial name
- NCT05515120
- Testing
- Rivaroxaban 20 MG [Xarelto], Aspirin 300mg, Acenocoumarol Oral Tablet
- Where
- Mexico
- Volunteers
- 58 people
- Sponsor
- Instituto Mexicano del Seguro Social
Sepsis
INFLAmmasomes NLRP3 in Platelets and Leukocytes During SEPSIS in Intensive Care Unit
septic shock is the first cause of mortality in intensive care unit. Innate immunity is the body's first line of defense against pathogens
- Trial name
- INFLA-SEPSIS (NCT04635878)
- Testing
- Blood collection
- Where
- France
- Volunteers
- 11 people
- Sponsor
- University Hospital, Toulouse